KT&G's Midterm Plan: Doubling Sales by 2027

Feb.02.2023
KT&G's Midterm Plan: Doubling Sales by 2027
KT&G plans to invest $3.1 billion in e-cigarette and ginseng health products and double sales by 2027.

KT&G has recently launched a midterm business plan.


According to the plan, KT&G will invest a total of 3.9 trillion Korean won (3.1 billion US dollars) by 2027, with a focus on its electronic cigarette business (including overseas operations) and health supplements containing ginseng.


KT&G has plans to increase its sales revenue to over 100 trillion Korean won by 2027, a 73% growth compared to the estimated sales revenue of 59 trillion Korean won in 2022.


Bang Kyung-man, the Executive Vice President of KT&G, announced that the company now sells its heated non-combustible cigarette brands in 31 different countries, with a primary focus on the European market. Since partnering with various companies, the sales of its product, "lil," have quadrupled. The company is also considering releasing sales data related to "lil," which has not yet been disclosed due to a partnership agreement with PMI.


The company also presented its business expansion strategy, aiming to obtain more than half of its sales revenue from overseas operations by 2027. It is reported that in 2022, about 33% of KT&G's sales revenue comes from overseas operations.


According to Bang, KT&G is considering Kazakhstan and Eastern Europe as potential locations for a new factory. In order to raise the necessary funds, KT&G may sell some of its real estate assets and borrow from banks.


References:


KT&G has rejected the idea of spinning off its ginseng unit and instead plans to double its sales by 2027.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Product | Compatible with 3ml/2ml Pods and Up to 45W Output: RELX Launches a New Open-System E-Cigarette on Its Indonesia Website
Product | Compatible with 3ml/2ml Pods and Up to 45W Output: RELX Launches a New Open-System E-Cigarette on Its Indonesia Website
RELX has launched the open-system RELX Prime Pro on its Indonesia website and has also rolled it out across multiple local e-commerce channels. According to publicly available product pages, the device is rated at up to 45W, features a 1350mAh battery, and is compatible with 3ml and 2ml pod capacities.
Dec.30 by 2FIRSTS.ai
JTI Expands Albania Distribution Through Partnership with Nelt
JTI Expands Albania Distribution Through Partnership with Nelt
Serbian logistics company Nelt Group said it has become a distributor for Japan Tobacco International products in Albania. According to the company, the partnership has created 50 new jobs in the local market. Nelt described the move as part of a broader change to its business model in Albania. The group already cooperates with JTI in Bosnia and Herzegovina and expects its revenue to grow by 9% in 2025.
Dec.23 by 2FIRSTS.ai
Interpreting FDA’s on! PLUS Authorization: What the Agency’s Press Release Reveals About Its Nicotine Pouch Review Model
Interpreting FDA’s on! PLUS Authorization: What the Agency’s Press Release Reveals About Its Nicotine Pouch Review Model
The U.S. Food and Drug Administration has confirmed that six on! PLUS nicotine pouch products have received Marketing Granted Orders (MGO) through the PMTA pathway. The authorizations were completed under the agency’s nicotine pouch review pilot program in “record time,” with the FDA citing lower levels of harmful constituents while stressing that the decision applies only to the specified products and does not mean they are safe or FDA approved.
Regulations
Dec.20
2Firsts Interview | Bengt Wiberg: Why the Oral Health Risks of Nicotine Pouches Merit Further Study
2Firsts Interview | Bengt Wiberg: Why the Oral Health Risks of Nicotine Pouches Merit Further Study
As nicotine pouches gain global traction as a lower-risk alternative to smoking, questions are emerging about their potential oral health effects. In a 2Firsts interview, Stingfree AB founder Bengt Wiberg discusses why gum irritation and oral lesions warrant closer scrutiny within the broader framework of tobacco harm reduction.
Jan.06
AIR Acquires Germany’s NameLess to Expand Global Presence in Flavored Hookah Market
AIR Acquires Germany’s NameLess to Expand Global Presence in Flavored Hookah Market
AIR Limited, the Dubai-based global leader in hookah and advanced inhalation technologies, announced the acquisition of NameLess, one of Germany’s most recognized brands for premium flavored hookah products.
Dec.11 by 2FIRSTS.ai
 Breaking News | FDA Adds on! Plus Nicotine Pouches to PMTA-Authorized List
Breaking News | FDA Adds on! Plus Nicotine Pouches to PMTA-Authorized List
The U.S. Food and Drug Administration (FDA) has added ON! Plus nicotine pouch products to its list of authorized products, disclosing that the brand has received Marketing Granted Orders (MGO) through the Premarket Tobacco Product Application (PMTA) pathway. The update makes on! Plus the second nicotine pouch brand authorized via PMTA, following ZYN. As of publication, the FDA had not issued a separate press release on the decision.
News
Dec.20